Glenmark Pharma Latest News
-
The Horizant market achieved annual sales of approximately $99.5 millionDate:31-12-2020
-
The Horizant market achieved annual sales of approximately $99.5 millionDate:31-12-2020
-
The Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market achieved annual sales of approximately $125.5 millionDate:31-12-2020
-
The fixed drug combination is indicated for the management of Type 2 diabetesDate:29-12-2020
-
The fixed drug combination is indicated for the management of Type 2 diabetesDate:29-12-2020
-
Glenmark Pharmaceuticals has informed that the company has attached media release on 23rd December 2020, titled ‘Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializi...
Date:23-12-2020 -
Glenmark will be responsible for the continued development and regulatory approval of Ryaltris in these marketsDate:23-12-2020
-
Glenmark will be responsible for the continued development and regulatory approval of Ryaltris in these marketsDate:23-12-2020
-
The 12 month period ending October 2020, the Pradaxa Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 millionDate:21-12-2020
-
The 12 month period ending October 2020, the Pradaxa Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 millionDate:21-12-2020